Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation

References

• Turner AM, Lin NL, Issarachai S, et al. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996;88:3383–3390.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532–1542.
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10: 1911–1918.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Muller-Tidow C, Berdel WE, et al. Signal transduction of oncogenic Flt3. Int J Hematol 2005;82:93–99.
   PubMed Web of Science ®Google Scholar
• Buchner T, Schlenk RF, Schaich M, et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm—combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012;30:3604–3610.
   PubMed Web of Science ®Google Scholar
• Schiller GJ. Evolving treatment strategies in patients with high-risk acute myeloid leukemia. Leuk Lymphoma 2014;55:2438–2448.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Zhang T, Ding X, Wei D, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 2010;21:326–332.
   PubMed Web of Science ®Google Scholar
• Escudier B. Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2011;11:825–836.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835–844.
   PubMed Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567–6571.
   PubMed Web of Science ®Google Scholar
• Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008;49:2246–2255.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Tallman MS, Polliack A. Sorafenib - a small molecule with big promise? Leuk Lymphoma 2010;51:181–182.
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013;31:3110–3118.
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96: 3907–3914.
   PubMed Web of Science ®Google Scholar
• Lange B, Valtieri M, Santoli D, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987;70:192–199.
   PubMed Web of Science ®Google Scholar
• Yao Q, Nishiuchi R, Li Q, et al. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003;9:4483–4493.
   PubMed Web of Science ®Google Scholar
• Yang E, Zha J, Jockel J, et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80:285–291.
   PubMed Web of Science ®Google Scholar
• Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619–628.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059–2074.
   PubMed Web of Science ®Google Scholar
• Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012;26:2353–2359.
   PubMed Web of Science ®Google Scholar
• Al-Riyami AZ, Hudoba M, Young S, et al. Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia. Leuk Lymphoma 2013;54:1788–1790.
   PubMed Web of Science ®Google Scholar
• Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999;6:559–568.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431–435.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427–430.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.
   PubMed Web of Science ®Google Scholar
• Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179–185.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Rampal R, Harding JJ, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012;367:2316–2321.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Messina JL, Fedorenko IV, et al. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10:390–399.
   PubMed Web of Science ®Google Scholar